EMA Recommends Approval Of AstraZeneca's COVID-19 Therapy, Evusheld

EMA's human medicines committee (CHMP) has recommended granting marketing authorization for AstraZeneca Plc's AZN Evusheld to prevent COVID-19 in adults and adolescents before potential exposure to the SARS-CoV-2 virus.

  • Evusheld is made of tixagevimab and cilgavimab, two monoclonal antibodies designed to attach to the spike protein of the SARS-CoV-2 virus (the virus that causes COVID-19) at two different sites. 
  • When the antibodies in Evusheld attach to the spike protein, the virus cannot enter the cells to multiply and is unable to cause COVID-19 infection.
  • The CHMP evaluated data from a study in over 5,000 people showing that Evusheld, given as two injections of 150 mg tixagevimab and 150 mg cilgavimab, reduced the risk of COVID-19 infection by 77%, with the duration of protection estimated to be at least six months. 
  • In the study, adults who had never had COVID-19 and had not received a COVID-19 vaccine or other preventative treatment received Evusheld or placebo. 
  • Of the people given Evusheld, 0.2% (8 out of 3,441) had lab-confirmed breakthrough COVID-19 after treatment, compared with 1.0% (17 out of 1,731) on the placebo.
  • Related: AstraZeneca's COVID-19 Antibody Neutralizes Omicron Sub-variants, Lab Study Shows.
  • EMA will assess data in the coming weeks to evaluate whether an alternative dosing regimen could be appropriate for preventing COVID-19 resulting from emerging variants.
  • Price Action: AZN shares are up 1.37% at $65.20 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsCOVID-19 CoronavirusEuropean Medicines Agency
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!